Pieris Pharmaceuticals, Inc. (PIRS)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Stephen S. Yoder J.D. | CEO, President & Director | 774.72k | -- | 1976 |
Mr. Thomas Bures | Senior VP, CFO & Treasurer | 499.38k | -- | 1975 |
Maria Kelman | Executive Director of Investor Relations | -- | -- | -- |
Dr. Shane Olwill Ph.D. | Senior VP & Chief Development Officer | -- | -- | 1976 |
Mr. Prompong Chaikul | Chief Supply Chain Officer | -- | -- | 1987 |
Dr. Florian Witte Ph.D. | VP and Head of Alliance Management & Early Project Leadership | -- | -- | -- |
Pieris Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 46
Description
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Corporate Governance
Recent Events
- Apr 18, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 29, 202410-K: Periodic Financial ReportsSee Full Filing
- Mar 27, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Dec 21, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 14, 202310-Q: Periodic Financial ReportsSee Full Filing